RECCE 435
Alternative Names: R 435; RECCE® 435Latest Information Update: 16 Oct 2024
Price :
$50 *
At a glance
- Originator Recce Pharmaceuticals
- Class Antibacterials; Polymers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Helicobacter infections
- Research Gonorrhoea
Most Recent Events
- 10 Oct 2024 RECCE 435 is still in preclinical trials for Helicobacter-infection and Gonorrhoea in Australia
- 28 Sep 2024 No recent reports of development identified for preclinical development in Helicobacter-infections in Australia (PO)
- 28 Sep 2024 No recent reports of development identified for research development in Gonorrhoea in Australia (PO)